SOAT1 and hepatocellular carcinoma: Avasimibe, a potent small molecule inhibitor of SOAT1 (Figure 4A), has been proven to exert anticancer effects against many tumors, including glioblastoma (GBM), hepatocellular carcinoma (HCC) and prostate cancer (PCa) (Tardif et al., 2004; Bemlih et al., 2010; Jiang et al., 2019; Liu et al., 2021).